贝林妥欧单抗治疗复发或难治性霍奇金淋巴瘤患者的长期生存结局：系统评价和荟萃分析。

Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.

机构信息

Department of Hematology, Henan Provincial People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou, China.

出版信息

Eur Rev Med Pharmacol Sci. 2021 Apr;25(7):2941-2948. doi: 10.26355/eurrev_202104_25547.

DOI:10.26355/eurrev_202104_25547

PMID:33877657

Abstract

OBJECTIVE

The short-term benefits of brentuximab vedotin (BV) for classical Hodgkin lymphoma (cHL) are well established, but its long-term benefits for refractory/relapsing (r/r) cHL are unknown. A meta-analysis was undertaken to examine the overall survival (OS), and progression-free survival (PFS) from relevant studies with patients with r/r cHL post-autologous stem cell transplantation (ASCT) exposed to BV.

MATERIALS AND METHODS

PubMed, Embase, and the Cochrane library were searched for available papers published up to January 2020. The main outcomes included 3-year OS/PFS and/or 5-year OS/PFS. Data were pooled using random-effects models.

RESULTS

Four studies were included: one randomized controlled trial, one single-arm trial, and two retrospective studies. The four studies included a total of 383 patients (mean of 95.75/study). The proportion of females was 21%-89%. The median age was 26-33 years. The 3-year OS was available for one study and was 41% in patients with r/r cHL with BV after ASCT (OR=0.41, 95% CI: 0.16-0.67). The 5-year OS was available for two studies and was 34% in patients with r/r cHL with BV after ASCT (OR=0.34, 95% CI: 0.19-0.48; mixed-effects model). The 5-year PFS was available for three studies and was 31% in patients with r/r cHL with BV after ASCT (OR=0.31, 95% CI: 0.02-0.61; mixed-effects model).

CONCLUSIONS

The 5-year OS in patients with r/r cHL treated with BV after ASCT is 34% (95 CI: 19%-48%). The 5-year PFS in patients with r/r cHL treated with BV after ASCT is 31% (95 CI: 2%-61%).

摘要

目的

博纳吐单抗（BV）治疗经典型霍奇金淋巴瘤（cHL）的短期疗效已得到充分证实，但对于自体造血干细胞移植（ASCT）后复发/难治性（r/r）cHL 的长期疗效尚不清楚。本研究通过对 r/r cHL 患者接受 BV 治疗后的相关研究进行荟萃分析，以评估其总生存期（OS）和无进展生存期（PFS）。

材料与方法

检索了截止至 2020 年 1 月发表的相关文献，包括 PubMed、Embase 和 Cochrane 图书馆。主要结局包括 3 年 OS/PFS 和（或）5 年 OS/PFS。使用随机效应模型进行数据合并。

结果

共纳入四项研究：一项随机对照试验、一项单臂试验和两项回顾性研究。四项研究共纳入 383 例患者（平均每例研究 95.75 例）。女性比例为 21%-89%。中位年龄为 26-33 岁。一项研究提供了 3 年 OS 数据，ASCT 后 r/r cHL 患者接受 BV 治疗的 3 年 OS 率为 41%（OR=0.41，95%CI：0.16-0.67）。两项研究提供了 5 年 OS 数据，ASCT 后 r/r cHL 患者接受 BV 治疗的 5 年 OS 率为 34%（OR=0.34，95%CI：0.19-0.48；混合效应模型）。三项研究提供了 5 年 PFS 数据，ASCT 后 r/r cHL 患者接受 BV 治疗的 5 年 PFS 率为 31%（OR=0.31，95%CI：0.02-0.61；混合效应模型）。